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TheBlue-Carba test (BCT) is a biochemical test for rapid (2 h)detection of carbapenemase production in Gram-negative ba-
cilli directly from bacterial culture (1). It is based on the in vitro
hydrolysis of imipenem by bacterial colonies (direct inoculation
without prior lysis), which is detected by changes in pH values
revealed by the indicator bromothymol blue (blue to green/yellow
or green to yellow). It was reported to be 100% sensitive and
specific for Enterobacteriaceae, Pseudomonas spp., andAcinetobac-
ter spp. harboring carbapenemases (1). We evaluated a simplified
protocol of the BCT against various Gram-negative species, in-
cluding combinations of bacterial species/resistance mechanisms
that were not previously evaluated.
A total of 300 clinical isolates were included (188 carrying
known carbapenemase-encoding genes and 112 without carbap-
enemase production) (Table 1). The isolates, belonging to the
collection of the National and Regional Reference Lab, corre-
spond to submissions from very diverse locations in Latin Amer-
ica (21 countries, 1,226 labs surveyed from 2010 to 2014) (2) and
thus should representminimal clonal and enzyme bias. PCR anal-
ysis was considered the gold standard for -lactamases character-
ization (for the primer pairs used, see Table S1 in the supplemental
material) (3). Outermembrane protein analysis was performed by
SDS-PAGE (4, 5). Efflux pump inhibitors were used for pheno-
typic screening of efflux pump activity (6). Chromosomally
mediated cephalosporinase hyperproduction was evaluated by
spectrophotometric analyses as described previously (3). Identifi-
cation to the species level was confirmed by matrix-assisted laser
desorption ionization–time of flight mass spectrometry (Bruker,
Germany). Imipenem MICs (agar dilution) and the modified
Hodge test (MHT) were performed and interpreted by using the
Clinical and Laboratory Standards Institute guidelines (6).
The BCT was performed by using a modified protocol as fol-
lows. Strains were grown on Mueller-Hinton agar, Trypticase soy
agar, and Columbia agar with 5% sheep blood plates. Subse-
quently, a 5-l loop of a pure bacterial culture from each type of
agar was resuspended in the test mixture, which consisted of an
aqueous solution of bromothymol blue at 0.04% (Sigma) and 0.1
mmol/liter ZnSO4 (Sigma) with (reaction tube) or without (con-
trol tube) supplementation with 6 mg of Tienam (MSD) (equiv-
alent to 3 mg of imipenem) and adjusted to a final pH of 7.0.
Unsupplemented mixture solution was stored at 4°C (pH adjust-
ments were needed every 4 to 6 weeks). The test solution was
supplemented with Tienam immediately before being used.
Strains were tested in duplicate. Two independent readers inter-
preted the results (interpretation discrepancies were recorded as
equivocal results).
The results of BCT according to our modified protocol were
100% coincident on all three agar types used for bacterial subcul-
tures. The BCT detected all class A carbapenemases (Table 1),
including those of two Klebsiella pneumoniae KPC-2 producers
with imipenem MICs of 0.12 g/ml (M15222) and 0.03 g/ml
(M13403) (7) and enzymes with slow imipenem hydrolysis, such
as theGES-type (n 3) or Sme-type (n 3) enzymes. Allmetallo-
beta-lactamases (MBLs) tested positive (Table 1), including those
from three strains with an imipenemMICof 0.25g/ml. The BCT
detected all Acinetobacter species isolates with acquired OXA car-
bapenemases but only 9 of 14 OXA-48-like enzyme-producing
Enterobacteriaceae isolates (Table 1). Misdetections occurred
among all of those OXA-48-like enzyme-producing Enterobacte-
riaceae isolates with MICs of1.0 g/ml; one OXA-48 producer
and one OXA-247 producer (MIC, 0.5 g/ml), both with equiv-
ocal results, and three OXA-163 producers (MICs, 0.12 to 0.5
g/ml) were negative. Therefore, the overall sensitivity and nega-
tive predictive value of the BCTwere 97 and 96%, respectively. All
carbapenemase nonproducers were negative by the BCT (Table
1), which confirmed the high specificity and positive predictive
value (100%) of the method described previously (1).
The BCT is an accurate and inexpensive way to unequivocally
identify class A and B carbapenemases as described previously (1).
Unlike other similar tests, such as the Carba NP (6, 8), the BCT
detected KPC/MBL production in isolates with extremely low
imipenemMICs.However, in our study, the BCTgave suboptimal
results for the identification of OXA-48-like enzyme producers,
with the largest amount of misdetections among the OXA-163
producers. The Carba NP has also shown limitations in the detec-
tion of OXA-48-like enzyme-producing Enterobacteriaceae, with
reported sensitivities of 11 to 100% (6, 8–10). The results observed
in this work could be linked to the low hydrolytic profile of OXA-
163 producers, although there is still an open debate on its role as
a carbapenemase. Whereas in vitro kinetic assays showed weak
carbapenemase activity (11), in vivo data have suggested that
OXA-163 per se could cause carbapenem treatment failure or fa-
vor the intrapatient selection of new OXA variants (12, 13).
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TABLE 1 Isolates tested,i imipenem susceptibility, and test results
Group and -lactamase (no. of
isolates) Bacterial species included (no. of isolates)
% of isolates
No. of isolates BCT
positive/no. (%) of
isolates testeda
Imipenem
nonsusceptible
MHT
positive
Class A carbapenemase producers
KPC-2 (51) K. pneumoniae (34), E. coli (5), E. cloacae (4), P. aeruginosa (3), C. freundii
(2), C. braakii (1), K. oxytoca (1), L. adecarboxylata (1)
88 100 51/51 (100)
KPC-3 (1) K. pneumoniae (1) 100 100 1/1 (100)
Sme-1b (3) S. marcescens (3) 100 0 3/3 (100)
GES-3 (2) E. cloacae (1), K. pneumoniae (1) 100 100 2/2 (100)
GES-5 (1) P. aeruginosa (1) 100 100 1/1 (100)
IMI-1/NMC-A (2) E. cloacae (2) 100 100 2/2 (100)
All (60) 90 95 60/60 (100)
Class B carbapenemase producers
NDM-1 (14) K. pneumoniae (4), E. coli (3), P. rettgeri (3), A. pittii (2), A. baumannii (1),
P. mirabilis (1)
100 21 14/14 (100)
IMP-1 (9) A. ursingii (4), A. lwoffii (2), A. junii (2), A. johnsonii (1) 89 100 9/9 (100)
IMP-8 (8) E. cloacae (4), E. coli (2), C. freundii (1), K. oxytoca (1) 88 100 8/8 (100)
IMP-13 (5) P. aeruginosa (5) 60 40 5/5 (100)
IMP-16 (4) P. aeruginosa (4) 50 50 4/4 (100)
IMP-18 (1) P. aeruginosa (1) 100 100 1/1 (100)
VIM-2 (26) P. aeruginosa (7), P. putida (7), P. monteilii (4), E. cloacae (1), K. pneumoniae
(1), P. chlororaphis (1), P. fulva (1), P. fluorescens, (1), P. oleovorans (1),
P. rettgeri (1), P. stutzeri (1)
92 92 26/26 (100)
VIM-11 (3) P. aeruginosa (2), E. cloacae (1) 67 100 3/3 (100)
VIM-1 (1) E. coli (1) 100 100 1/1 (100)
SPM-1 (5) P. aeruginosa (5) 100 100 5/5 (100)
All (76) 89 89 76/76 (100)
Class D carbapenemase producers
OXA-48 (5) E. coli (3), K. oxytoca (1), K. pneumoniae (1) 60 100 4/5 (80)
OXA-163 (5) K. pneumoniae (3), E. cloacae (1), K. georgiana (1) 20 100 2/5 (40)
OXA-247 (2) E. coli (1), K. pneumoniae (1) 50 100 1/2 (50)
OXA-181 (1) K. pneumoniae (1) 100 100 1/1 (100)
OXA-438 (1)b E. coli (1) 100 100 1/1 (100)
All Enterobacteriaceae OXA
producers (14)
46 100 9/14 (64)
OXA-58 (20) A. baumannii (7), A. lwoffii (6), A. junii (5), A. pittii (1), A. ursingii (1) 90 90 20/20 (100)
OXA-23 (14) A. baumannii (9), A. lwoffii (3), A. junii (2) 100 100 14/14 (100)
OXA-23 OXA-58 (3) A. baumannii (3) 100 100 3/3 (100)
OXA-143 (1) A. baumannii (1) 100 100 1/1 (100)
All Acinetobacter OXA
producers (38)
94 94 38/38 (100)
Carbapenemase nonproducers
ESBLs porin loss (38)c K. pneumoniae (30), E. coli (4), E. cloacae (2), S. marcescens (2) 87 45 0/38 (0)
ESBLs (11)d A. baumannii (4), P. aeruginosa (4), S. flexneri (2), P. putida (1) 0 0 0/11 (0)
AmpCs porin loss (16)e E. cloacae (10), E. aerogenes (3), C. freundii (2), E. coli (1) 88 81 0/16 (0)
AmpCs (12)f P. aeruginosa (9), E. coli (1), K. pneumoniae (1), P. mirabilis (1) 0 0 0/12 (0)
Narrow spectrum (5)g A. baumannii (2), P. aeruginosa (2), E. coli (1) 0 0 0/5 (0)
None (30)h P. aeruginosa (29), E. coli (1) 77 0 0/30 (0)
All nonproducers (112) 62 27 0/112 (0)
a A color change from blue or green (control tube) to green/yellow or yellow (reaction tube), respectively, was interpreted as a positive result; when both tubes (control and
reaction) remained either blue or green, the test was interpreted as negative. No invalid results were obtained (a yellow control tube).
b Novel OXA-48-like variant (GenBank accession no. KP410734).
c CTX-M-2, n 31; CTX-M-15, n 5; SHV-18, n 1; SHV-5, n 1.
d GES-1, n 5; CTX-M-2, n 2; PER-2, n 2; VEB-1, n 2.
e Hyperproduction of chromosomally mediated cephalosporinase, n 15; CMY-2, n 1.
f Hyperproduction of chromosomally mediated cephalosporinase, n 9; CMY-2, n 2; DHA-1, n 1.
g OXA-1, n 2; OXA-51 (without upstream ISAbaI), n 2; TEM-1, n 1.
h Nonenzymatically carbapenem-resistant isolates and quality control strains, i.e., Pseudomonas aeruginosa carbapenem resistant because of efflux overproduction (n 5), porin
loss (n 3), or dual mechanisms (n 20) and quality control strains P. aeruginosa ATCC 27853 and Escherichia coli ATCC 25922.
i Tested were 155 Enterobacteriaceae, 89 Pseudomonas, and 56 Acinetobacter isolates.
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In conclusion, for labs concernedwith thewidely disseminated
class A KPC producers, class D MBL (e.g., NDM) producers, and
class D OXA carbapenemase-producing Acinetobacter, the BCT
could be an accurate and cost-effective way to rapidly identify
potential carrier isolates. For somemechanisms, such as OXA-48-
like enzyme-producing Enterobacteriaceae, the total number of
isolates studied was low; however, preliminary results suggest that
in scenarios with an increasing prevalence of this mechanism, a
negative result with the BCT could require additional tests such as
the MHT (which showed 100% sensitivity in this study), prefera-
bly in combination with temocillin or piperacillin-tazobactam
susceptibility results (14).
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